Australian Securities Exchange

MGC Pharma Rebrands as Argent BioPharma in Strategic Transformation

Retrieved on: 
Tuesday, February 13, 2024

LONDON, Feb. 13, 2024 /PRNewswire/ -- MGC Pharmaceuticals Ltd (LSE: MXC), (OTC: MGCLF), (ASX: MXC)  Rebrands as Argent BioPharma in Strategic TransformationMarking a significant milestone in its evolutionary journey, MGC Pharma has officially announced its rebranding to Argent BioPharma, pending approval from its shareholders. This rebranding is the culmination of an extensive restructuring, incorporating significant American capital and operational revisions. Poised for growth, Argent BioPharma is now set to emerge as a key player in the biopharmaceutical industry, leveraging cutting-edge advancements in Polypharmacology and Nanotechnology. With its presence on both the London Stock Exchange and the Australian Stock Exchange, Argent BioPharma is well-positioned to make substantial contributions to enhancing medical treatment accessibility.

Key Points: 
  • LONDON, Feb. 13, 2024 /PRNewswire/ -- MGC Pharmaceuticals Ltd (LSE: MXC), (OTC: MGCLF), (ASX: MXC)  Rebrands as Argent BioPharma in Strategic Transformation
    Marking a significant milestone in its evolutionary journey, MGC Pharma has officially announced its rebranding to Argent BioPharma, pending approval from its shareholders.
  • Poised for growth, Argent BioPharma is now set to emerge as a key player in the biopharmaceutical industry, leveraging cutting-edge advancements in Polypharmacology and Nanotechnology.
  • With its presence on both the London Stock Exchange and the Australian Stock Exchange, Argent BioPharma is well-positioned to make substantial contributions to enhancing medical treatment accessibility.
  • As Argent BioPharma transitions from MGC Pharma, it stands ready to lead a new era in biopharmaceuticals, promising accessible and impactful healthcare solutions on a global scale.

Metals Acquisition Limited Initial Offering in Connection with ASX Listing Oversubscribed and Upsized to ~A$325million

Retrieved on: 
Friday, February 9, 2024

The Offer is being undertaken in connection with MAC’s dual listing on the Australian Securities Exchange (“ASX”).

Key Points: 
  • The Offer is being undertaken in connection with MAC’s dual listing on the Australian Securities Exchange (“ASX”).
  • The final price for the Offer has been set at the top of the indicative price range, being A$17.00 (~US$11.18)1 per CDI.
  • Barrenjoey Markets Pty Limited and Canaccord Genuity (Australia) Limited are acting as joint lead managers to the IPO (“Joint Lead Managers”).
  • Gilbert + Tobin, Skadden, Arps, Slate, Meagher & Flom and Ogier are acting as Australian, US and Jersey legal advisors to the Company in relation to the offer and ASX listing.

Piedmont Lithium Provides Corporate Update

Retrieved on: 
Tuesday, February 6, 2024

Piedmont Lithium (“Piedmont” or the “Company”) (Nasdaq: PLL; ASX: PLL), a leading global supplier of lithium resources critical to the U.S. electric vehicle (“EV”) supply chain, today provided an update on key business and portfolio activities.

Key Points: 
  • Piedmont Lithium (“Piedmont” or the “Company”) (Nasdaq: PLL; ASX: PLL), a leading global supplier of lithium resources critical to the U.S. electric vehicle (“EV”) supply chain, today provided an update on key business and portfolio activities.
  • “We are very pleased with the progress at NAL and anticipate continued operating improvements through 2024," said Keith Phillips, President and Chief Executive Officer of Piedmont Lithium.
  • Our projects include our Carolina Lithium and Tennessee Lithium projects in the United States and partnerships in Quebec with Sayona Mining (ASX: SYA) and in Ghana with Atlantic Lithium (AIM: ALL; ASX: A11).
  • Piedmont disclaims any intent or obligation to update publicly such forward-looking statements, projections, and estimates, whether as a result of new information, future events or otherwise.

Capstone Copper Commences Trading on the Australian Securities Exchange

Retrieved on: 
Friday, February 2, 2024

Capstone Copper Corp. (“Capstone”, “CS” or the “Company”) (TSX: CS) (ASX: CSC) today announced that the Australian Securities Exchange (“ASX”) approved the Company’s secondary listing on the ASX.

Key Points: 
  • Capstone Copper Corp. (“Capstone”, “CS” or the “Company”) (TSX: CS) (ASX: CSC) today announced that the Australian Securities Exchange (“ASX”) approved the Company’s secondary listing on the ASX.
  • Capstone Copper was admitted to the official list of the ASX, as an ASX Foreign Exempt Listing, on Wednesday, January 31, 2024 (AEDT) (Tuesday, January 30, 2024 (EST)).
  • Official quotation of Capstone CHESS Depositary Interests (“CDIs”) commenced at 12:00 p.m. (AEDT) on Friday February 2, 2024 (8:00 p.m. (EST) on Thursday, February 1, 2024) under the ticker symbol “CSC” (ASX: CSC).
  • Each CDI will represent one fully paid share of common stock of Capstone Copper.

Burgundy Diamond Mines reports fourth quarter results

Retrieved on: 
Thursday, January 25, 2024

CALGARY, Alberta, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Burgundy Diamond Mines (ASX:BDM) (Burgundy or the company) provided its financial and operating results for the fourth quarter (Q4 2023) ended December 31, 2023 to the Australian Stock Exchange (ASX), on January 24, 2024.

Key Points: 
  • CALGARY, Alberta, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Burgundy Diamond Mines (ASX:BDM) (Burgundy or the company) provided its financial and operating results for the fourth quarter (Q4 2023) ended December 31, 2023 to the Australian Stock Exchange (ASX), on January 24, 2024.
  • “Burgundy’s transformational acquisition of Ekati in July 2023 has delivered a positive and exciting period for the company with increased revenue, diamond sales, tonnes processed, and carats recovered at Ekati during the fourth quarter of 2023,” said Kim Truter, Burgundy Diamond Mines Chief Executive Officer and Managing Director.
  • Fourth quarter highlights (three months ended December 31, 2023):
    Currency is presented in US dollars.
  • Carats recovered: 1.2 million, up 19% (Q4 2022: 1.0 million), including a 75-carat rough diamond.

ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2024

Retrieved on: 
Wednesday, January 24, 2024

SAN DIEGO, Jan. 24, 2024 (GLOBE NEWSWIRE) -- ResMed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended December 31, 2023.

Key Points: 
  • Gross margin decreased by 50 basis points mainly due to costs associated with a field safety notification for masks with magnets.
  • SG&A expenses improved to 19.1 percent of revenue in the quarter, compared with 20.5 percent in the same period of the prior year.
  • ResMed has received a waiver from the ASX’s settlement operating rules, which will allow ResMed to defer processing conversions between its common stock and CDI registers from February 7, 2024, through February 8, 2024, inclusive.
  • ResMed will discuss its second quarter fiscal year 2024 results on its webcast at 1:30 p.m. U.S. Pacific Time today.

Bionomics Provides a Review of 2023 and of 2024 Plans

Retrieved on: 
Monday, January 22, 2024

ADELAIDE, Australia and CAMBRIDGE, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today provided a 2023 review and its outlook for 2024.

Key Points: 
  • ADELAIDE, Australia and CAMBRIDGE, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today provided a 2023 review and its outlook for 2024.
  • “Bionomics continued its evolution into a U.S.-focused, late-stage clinical company last year.
  • Voluntarily delisted from the Australian Stock Exchange in August 2023 and is currently solely listed on the NASDAQ Global Market.
  • Bionomics continues to plan the initiation of its first Phase 3 study of BNC210 in patients with SAD.

Metals Acquisition Limited Progresses Australian Securities Exchange Dual Listing with Lodgement of Prospectus

Retrieved on: 
Friday, January 26, 2024

As previously announced, Metals Acquisition Limited (NYSE:MTAL) (“MAC” or the “Company”) has been progressing a secondary listing on the Australian Securities Exchange (“ASX”) and is pleased to provide an update in relation to its proposed ASX listing.

Key Points: 
  • As previously announced, Metals Acquisition Limited (NYSE:MTAL) (“MAC” or the “Company”) has been progressing a secondary listing on the Australian Securities Exchange (“ASX”) and is pleased to provide an update in relation to its proposed ASX listing.
  • The Shares underlying the CDIs will rank equally with the Shares currently on issue in the Company.
  • Barrenjoey Markets Pty Limited and Canaccord Genuity (Australia) Limited are acting as joint lead managers to the IPO (“Joint Lead Managers”).
  • An indicative timetable in relation to the Offer and Listing is set out below.

Metals Acquisition Limited Provides Operational Update

Retrieved on: 
Wednesday, January 24, 2024

The average received copper price before hedge settlements was up marginally quarter on quarter to US$3.85/lb compared to $3.81/lb in the prior period.

Key Points: 
  • The average received copper price before hedge settlements was up marginally quarter on quarter to US$3.85/lb compared to $3.81/lb in the prior period.
  • As seen in Figure 4, C1 cash costs increased marginally quarter on quarter.
  • Figure 5 provides an illustration of the improvements in productivity at the mine with a reduction in tonnes milled per employee given the increase in milled grade.
  • Figure 6 illustrates the improvement in the mining unit rate since MAC took ownership of the mine.

Piedmont Lithium Sells Portion of Atlantic Shares to Assore

Retrieved on: 
Thursday, January 18, 2024

Piedmont Lithium (“Piedmont” or the “Company”) (Nasdaq: PLL; ASX: PLL), a leading global supplier of lithium resources critical to the U.S. electric vehicle supply chain, today announced an agreement to sell a portion of shares it holds in Atlantic Lithium (“Atlantic”) (AIM: ALL; ASX: A11) to Atlantic’s largest shareholder, Assore International Holdings (“Assore”).

Key Points: 
  • Piedmont Lithium (“Piedmont” or the “Company”) (Nasdaq: PLL; ASX: PLL), a leading global supplier of lithium resources critical to the U.S. electric vehicle supply chain, today announced an agreement to sell a portion of shares it holds in Atlantic Lithium (“Atlantic”) (AIM: ALL; ASX: A11) to Atlantic’s largest shareholder, Assore International Holdings (“Assore”).
  • The shares to be sold represent approximately 3.9% of Atlantic’s outstanding shares and will result in approximately US$7.8 million in proceeds for Piedmont.
  • Piedmont will retain 32.7 million Atlantic shares, representing approximately 5.2% ownership in Atlantic.
  • We have always viewed our Atlantic shares as a potential source of capital and are pleased to further bolster our cash balance through this agreement,” said Keith Phillips, President and CEO of Piedmont Lithium.